

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or as to what action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are a resident of the United Kingdom or, if not, another appropriately authorised independent professional adviser. This document does not contain nor should its contents be construed as legal, business or tax advice and you should consult your own solicitor, independent financial adviser or tax adviser (as appropriate) for such advice. No person has been authorised to give any information or make any representations other than those contained in this document and, if given or made, such information or representations must not be relied on as having been authorised by CRISM Therapeutics Corporation (the “Company”).

If you have sold or otherwise transferred all of your Ordinary Shares, please send this document and the accompanying proxy form as soon as possible to the purchaser or transferee, or to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some (but not all) of your Ordinary Shares, please retain these documents and consult the stockbroker or other agent through whom the sale or transfer was effected.

This document should be read in its entirety. Your attention is drawn to the letter from the Executive Chairman in this document, recommending you vote in favour of the resolutions to be proposed at the General Meeting.



CRISM Therapeutics Corporation

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

CONDITIONAL PLACING, RETAIL OFFER AND NOTICE OF

GENERAL MEETING

**SP
ANGEL.**

Nominated Adviser and Broker

SP Angel Corporate Finance LLP

Notice convening the General Meeting of Shareholders to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT, UK on 15 June 2026 at 10.00 a.m. is set out at the end of this document. A Form of Proxy for holders of Ordinary Shares for use at the General Meeting accompanies this document and, to be valid, must be completed and returned to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL.

As an alternative to completing the hard copy Form of Proxy, you can appoint a proxy electronically online at <https://uk.investorcentre.mpms.mufg.com/> and by completing the authentication requirements as set out on the Form of Proxy. Alternatively, you can vote via the Investor Centre app (refer to the notes to the Notice of General Meeting). For an electronic proxy appointment to be valid, your appointment must be received by the Company's registrars, MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event no later than 10.00 a.m. on 11 June 2026.

A Form of Direction for holders of Depository Interests for use at the General Meeting of Shareholders accompanies this document and, to be valid, must be completed and returned to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event to be received not later than 10.00 a.m. on 10 June 2026. The return of one or more completed Forms of Proxy or Forms of Direction will not prevent you from attending the General Meeting and voting in person if you wish to do so (and are so entitled).

Depository Interest holders who are also CREST members may transmit voting instructions by utilising the CREST voting service in accordance with the procedures described in the CREST Manual (refer to the notes to the Notice of GM).

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io and refer to the notes to the Notice of GM.

A summary of the action to be taken by Shareholders of the Company is set out in the Notice of GM at the end of this document. Copies of this document will be available free of charge from the Company's registered office during normal business hours on each day (excluding Saturday, Sunday and public holidays) from the date hereof until the date of the General Meeting. Copies will also be available from the Company's website at www.crismltherapeutics.com.

FUNDRAISING AND SHARE CAPITAL STATISTICS

| | |
|--|-----------------|
| Issue price | 10 pence |
| Number of Ordinary Shares prior to the Placing and the Retail Offer | 51,735,266 |
| Number of Firm Placing Shares | 2,500,000 |
| Number of Conditional Placing Shares | 22,500,000 |
| Number of Retail Offer Shares | up to 1,000,000 |
| Total number of Firm Placing Shares, Conditional Placing Shares and Retail Offer Shares* | 26,000,000 |
| Percentage of the Enlarged Share Capital represented by the Firm Placing Shares, Conditional Placing Shares and Retail Offer Shares* | 33.4 per cent. |
| Total number of Warrants issued pursuant to the Placing | 25,000,000 |
| Gross proceeds of the Placing and the Retail Offer* | £2,600,000 |
| Number of Ordinary Shares in issue immediately following First Admission | 54,235,266 |
| Number of Ordinary Shares in issue immediately following Second Admission* | 77,735,266 |

* assuming the maximum number of Retail Offer Shares are subscribed for in the Retail Offer

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

| | |
|--|----------------------------|
| Circular posted to Shareholders | 27 May 2026 |
| First Admission | 28 May 2026 |
| Latest time and date for receipt of CREST voting instructions | 10 June 2026 |
| Latest time and date for receipt of Form of Direction | 10 June 2026 |
| Latest time and date for receipt of Form of Proxy | 11 June 2026 |
| Expected dispatch of definitive share certificates in respect of the Firm Placing Shares in certificated form | 11 June 2026 |
| General Meeting | 10.00 a.m. on 15 June 2026 |
| Second Admission | 16 June 2026 |
| Expected dispatch of definitive share certificates in respect of the Conditional Placing Shares and the Retail Offer Shares in certificated form | 30 June 2026 |

DEFINITIONS

The following definitions apply throughout this document, unless the context otherwise requires:

| | |
|-------------------------------------|--|
| “Articles” | the memorandum and articles of association of the Company as the same are in force at any applicable time |
| “Board” or “Directors” | the directors of the Company whose names are set out on page 5 of this document |
| “BookBuild” | BB Technology Limited, a company incorporated in England and Wales (company number 1350812) whose registered office is at Kinetic Business Centre, Theobald Street, Elstree, Hertfordshire, England, WD6 4PJ |
| “Company” or “CRISM” | CRISM Therapeutics Corporation, a company registered in the British Virgin Islands with registered number 1010359 and having its registered office at Kingston Chambers, P.O. Box 173, Road Town, Tortola, British Virgin Islands |
| “Conditional Placing” | the conditional placing of the Conditional Placing Shares at the Issue Price, subject to the approval of Shareholders at the General Meeting |
| “Conditional Placing Shares” | 22,500,000 new Ordinary Shares to be issued by the Company pursuant to the Conditional Placing |
| “CREST” | the computerised settlement system operated by Euroclear which facilitates the transfer of title to shares in uncertificated form |
| “CREST Manual” | the document of that name issued by Euroclear |
| “CREST Voting Instruction” | a message by or on behalf of Depository Interest holders in connection with the General Meeting transmitted through CREST properly authenticated in accordance with Euroclear’s specifications and containing the information required for such instructions in the CREST Manual |
| “Depository Interests” | the depository interests representing Ordinary Shares |
| “Euroclear” | Euroclear UK & International Limited, the operator of CREST |
| “Firm Placing” | the placing of Firm Placing Shares at the Issue Price |
| “Firm Placing Shares” | 2,500,000 new Ordinary Shares issued by the Company at the Issue Price under the existing shareholders’ authorities granted at the Company’s annual general meeting on 26 August 2025 |
| “First Admission” | admission of the Firm Placing Shares to trading on AIM, which will be effective at 8.00 a.m. on 28 May 2026 |
| “Form of Direction” | the form of direction for use by Depository Interest holders in connection with the General Meeting |
| “Form of Proxy” | the form of proxy for use by Shareholders at the GM |
| “Fundraising” | together, the Placing and the Retail Offer |
| “General Meeting” or “GM” | the General Meeting of the Company convened for 15 June 2026 to approve the Resolutions, or any adjournment of that meeting; |

| | |
|-----------------------------------|---|
| “Group” | the Company and its subsidiaries |
| “Issue Price” | 10 pence per Ordinary Share |
| “Notice of GM” or “Notice” | the notice of General Meeting found at the end of this document |
| “Ordinary Shares” | the ordinary shares of no par value in the Company |
| “Placing” | the Placing of Firm Placing Shares and Conditional Placing Shares to raise gross proceeds of £2,500,000 |
| “Placing Shares” | the Firm Placing Shares and the Conditional Placing Shares |
| “Resolutions” | the resolutions to be proposed at the General Meeting as set out in the notice of General Meeting set out at the end of this document |
| “Retail Offer” | the offer of Retail Offer Shares to certain investors in the United Kingdom undertaken by BookBuild on behalf of the Company, subject to the approval of Shareholders at the General Meeting |
| “Retail Offer Shares” | up to 1,000,000 new Ordinary Shares to be issued to retail investors at the Issue Price pursuant to the Retail Offer, subject to approval of the Shareholders at the General Meeting |
| “Second Admission” | admission of the Conditional Placing Shares and the Retail Offer Shares to trading on AIM, expected to become effective at 8.00 a.m. on or around 16 June 2026 |
| “Shareholders” | holders of Ordinary Shares and, where the context requires, Depository Interests |
| “Warrants” | the 25,000,000 warrants entitling holders to the issue of one Ordinary Share per Warrant at an exercise price of 15p per new Ordinary Share granted to participants of the Placing, subject to approval of Shareholders |

CRISM Therapeutics Corporation

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

Directors:

Andrew Webb (*Executive Chairman*)
Prof Chris McConville (*Chief Scientific Officer*)
Gerald Beaney (*Non-executive Director*)

Registered Office:

Kingston Chambers
P.O. Box 173
Road Town
Tortola
British Virgin Islands

27 May 2026

Notice of General Meeting

Dear Shareholder,

On 26 May 2026, the Company announced details of a fundraising, consisting of:

- a Firm Placing of 2,500,000 new Ordinary Shares at the Issue Price to raise £250,000;
- a Conditional Placing of 22,500,000 new Ordinary Shares at the Issue Price, subject to the approval of Shareholders at the General Meeting, to raise £2,250,000;
- a conditional issue of Warrants to participants in the Placing on the basis of one Warrant for every Placing Share; and
- a Retail Offer of up to 1,000,000 new Ordinary Shares at the Issue Price through BookBuild to certain eligible retail investors to raise gross proceeds of up to £100,000.

The Company will require further share authorities to allot the Conditional Placing Shares, the Warrants and the Retail Offer Shares. Accordingly, the Conditional Placing, the issue of Warrants and the Retail Offer are each conditional, *inter alia*, upon Shareholders approving the Resolutions at a General Meeting to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT on 15 June 2026 at 10.00 a.m., notice of which is set out at the end of this document. A Form of Proxy or a Form of Direction for use in connection with the General Meeting is enclosed with this document.

The purpose of this document, is to explain the background to, and reasons for, the Fundraising and why the Directors believe that the Fundraising is in the best interests of the Company and its Shareholders as a whole and to recommend that you vote in favour of the Resolutions.

Background to the Placing and Retail Offer

During 2025, the Company largely utilised existing share issuance authorities through equity placings in July and December, raising gross proceeds of over £1.9 million. These proceeds have allowed the Company to make significant progress on its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma, with proceeds used to set up the clinical trial and manufacture the good manufacturing practice (“**GMP**”) compliant clinical batch of irinotecan-ChemoSeed for the clinical trial.

As the Company is pre-revenue, it is reliant on its ability to access capital until such time as it achieves profitability and positive cash flow.

Funds raised from the Placing and Retail Offer will provide the Company with the finance needed to help secure significant grant funding (subject to confirmation) and further enable the Company to progress its Phase 2 open-label clinical trial, with the first patients expected to be dosed in June 2026. The net proceeds will also allow the continued development of docetaxel-ChemoSeed for treatment of prostate cancer, which has demonstrated significant positive preclinical efficacy and safety results.

The authority granted by the Resolutions will, to the extent it is unused, terminate at the next annual general meeting.

The Directors believe that the Placing and Retail Offer are in the best interests of CRISM Shareholders.

Principal terms of the Fundraising

The Placing

The Company has conditionally raised approximately £2,500,000 (before expenses) by way of a placing of 25,000,000 new Ordinary Shares at a price of 10 pence per share. The Placing Shares have been conditionally placed with institutional investors and certain existing Shareholders. The Placing is not being underwritten. Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM.

The Placing Shares each have an attaching grant of Warrants on a one for one basis, exercisable at a price of 15 pence per ordinary share and expiring on 16 December 2027.

The Placing is being conducted in two tranches. The Firm Placing will utilise the existing authority to grant shares granted at the Company's annual general meeting on 26 August 2025 and is therefore only conditional on First Admission becoming effective on or before 8.00 a.m. on 28 May 2026 (or such later time and/or date as SP Angel and the Company may agree, not being later than 11 June 2026).

The Conditional Placing and the issue of Warrants are conditional on the following:

- First Admission taking place as described above;
- the Resolutions being passed at the General Meeting; and
- Second Admission having become effective on or before 8.00 a.m. on 16 June 2026 (or such later time and/or date as SP Angel and the Company may agree, not being later than 30 June 2026).

The Retail Offer

On 26 May 2025 the Company announced the launch of the Retail Offer through the offer of up to 1,000,000 Retail Offer Shares at the Issue Price through the BookBuild platform to raise gross proceeds of up to £100,000. The Retail Offer is conditional on the following:

- First Admission taking place as described above;
- the Resolutions being passed at the General Meeting; and
- Second Admission having become effective on or before 8.00 a.m. on 16 June 2026 (or such later time and/or date as SP Angel and the Company may agree, not being later than 30 June 2026).

Use of proceeds of the Fundraising

The net proceeds of the Fundraising will:

- Provide the Company with the finance required to help secure significant grant funding, subject to confirmation;
- Progress the Phase 2 open-label clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma;
- Support the continued development of docetaxel-ChemoSeed for prostate cancer; and
- Provide the Company with additional working capital.

Business at the GM

The General Meeting of the Company is to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT, UK on 15 June 2026 at 10.00 a.m. The following Resolutions will be proposed at the General Meeting.

Resolution 1 – Authority to allot Ordinary Shares

Resolution 1 is an ordinary resolution to authorise the Directors to issue and allot Ordinary Shares. The Articles require that the authority of Directors to allot Ordinary Shares and to make offers or agreements to allot Ordinary Shares in the Company or grant rights to subscribe for or convert any security into Ordinary Shares should be subject to the approval of Shareholders in a general meeting except in connection with an employees' share scheme.

Accordingly, Resolution 1 will be proposed to authorise the Directors to allot up to 61,500,000 Ordinary Shares in relation to the issue of the Conditional Placing Shares, the Retail Offer Shares and the Warrants and including authority over 13,000,000 Ordinary Shares to provide flexibility to the Directors to take advantage of positive circumstances, should they arise, and raise further funds prior to the Company's 2026 annual general meeting. Such authority, if granted, will expire at the conclusion of the next annual general meeting of the Company to be held in 2026.

Resolution 2 – Dis-application of pre-emption rights

Resolution 2 is a special resolution to disapply pre-emption rights in respect of Ordinary Shares. The Articles require that any equity shares issued wholly for cash must be offered to existing Shareholders in proportion to their existing shareholdings unless otherwise approved by Shareholders in a general meeting except in the case of an employees' share scheme.

A special resolution (which will require votes in favour of not less than 75 per cent. of the votes cast by Shareholders voting in person or by proxy at the GM in order to be passed) will be proposed at the GM to give the Directors authority to allot equity securities for cash other than on a pro rata basis in respect of the issue of up to 61,500,000 Ordinary Shares in relation to the issue of the Conditional Placing Shares, the Retail Offer Shares and the Warrants and including authority over 13,000,000 Ordinary Shares to provide flexibility to the Directors to take advantage of positive circumstances, should they arise, and raise further funds prior to the 2026 Annual General Meeting. Such authority, if granted, will expire at the conclusion of the next annual general meeting of the Company to be held in 2026.

Action to be taken in respect of the GM

Whether or not you intend to be present at the General Meeting, shareholders are requested to complete, sign and return your Form of Proxy to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible and in any event not later than 10.00 a.m. on 11 June 2026, being 48 hours (not taking into account any part of a day which is not a working day in England & Wales) before the time appointed for holding the General Meeting.

Completion of a Form of Proxy will not preclude Shareholders from attending the General Meeting and voting in person if they so choose,

Proxies may be appointed by either:

- completing and returning the enclosed proxy form;
- appointing a proxy electronically online at <https://uk.investorcentre.mpms.mufg.com/>; or
- voting via the Investor Centre app.

In either case, the notice of appointment of a proxy should reach the Company's registrars, MUFG Corporate Markets of PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 10.00 a.m. on 11 June 2026. Please refer to the Notes to the Notice of General Meeting on page 10 and any enclosed proxy form for detailed instructions.

Holders of Depository Interests are requested to complete, sign and return a Form of Direction appointing MUFG Corporate Markets Trustees (Nominees) Limited (the "**Custodian**") to vote the underlying Ordinary Shares on their behalf at the General Meeting to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL, as soon as possible but in any event no later than 10.00 a.m. on 10 June 2026. A holder of Depository Interests has no right to attend and vote in relation to the underlying Ordinary Shares at the General Meeting and should therefore complete and return the Form of Direction so that the Custodian may vote on their behalf. However, if either a holder of Depository Interests or their representative does wish to attend and/or vote at the General Meeting they should request a Letter of Representation from the Custodian in accordance with the instructions on the Form of Direction.

Holders of Depository Interests in CREST may transmit voting instructions by utilising the CREST voting service in accordance with the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider, should refer to their CREST sponsor or voting service provider, who will be able to take appropriate action on their behalf.

In order for instructions made using the CREST voting service to be valid, the appropriate CREST message (a “**CREST Voting Instruction**”) must be properly authenticated in accordance with Euroclear’s specifications and must contain the information required for such instructions, as described in the CREST Manual (available via www.euroclear.com).

To be effective, the CREST Voting Instruction must be transmitted so as to be received by the Company’s agent (ID RA10) no later than 10.00 a.m. on 10 June 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the CREST Voting Instruction by the CREST applications host) from which the Company’s agent is able to retrieve the CREST Voting Instruction by enquiry to CREST in the manner prescribed by CREST. Holders of Depository Interests in CREST and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the transmission of CREST Voting Instructions. It is the responsibility of the Depository Interest holder concerned to take (or, if the Depository Interest holder is a CREST personal member or sponsored member or has appointed a voting service provider, to procure that the CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a CREST Voting Instruction is transmitted by means of the CREST voting service by any particular time. In this connection, Depository Interest holders and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your instruction must be lodged by 10.00 a.m. on 10 June 2026 in order to be considered valid or, if the meeting is adjourned, by the time which is 72 hours before the time of the adjourned meeting. Before you can submit an instruction via this process you will need to have agreed to Proxymity’s associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic submission of your instruction. An electronic submission via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your submission.

Admission

The Firm Placing Shares were issued by the Company under existing Shareholders’ authorities granted at the Company’s last annual general meeting held on 26 August 2025. Application has been made to the London Stock Exchange for admission of the Firm Placing Shares to trading on AIM and First Admission is expected to become effective and dealing to commence in the Firm Placing Shares at 8.00 a.m. on 28 May 2026.

Subject to the Resolutions being passed at the General Meeting, application will be made to the London Stock Exchange for admission of the Conditional Placing Shares and the Retail Offer Shares to trading on AIM after the General Meeting and it is expected that Second Admission will become effective and dealings will commence in the Conditional Placing Shares and the Retail Offer Shares at 8.00 a.m. on or around 16 June 2026.

Recommendation

The Board believes that the Resolutions being put to the Shareholders as described in this letter are in the best interests of the Company and its members as a whole and are likely to promote the success of the Company for the benefit of its members as a whole.

Accordingly, the Directors unanimously recommend that you vote in favour of the Resolutions to be proposed at the GM as they intend to do in respect of their own beneficial holdings of 12,558,016 Ordinary Shares, amounting to 24.27 per cent. of the existing issued share capital.

Yours sincerely

Andrew Webb
Executive Chairman

CRISM THERAPEUTICS CORPORATION

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

NOTICE OF GENERAL MEETING

Unless otherwise expressly stated, all defined terms referred to below shall have the same meaning as given in the circular dated 27 May 2026 (the “Circular”) of which the Notice convening this General Meeting forms part.

Notice is hereby given that the General Meeting of CRISM Therapeutics Corporation will be held at the office of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT, UK at 10.00 a.m. on 15 June 2026 to consider and, if thought fit, pass the following resolutions which will be proposed as to resolution 1 as an ordinary resolution and as to resolution 2 as a special resolution.

ORDINARY RESOLUTION

1. THAT the Directors be and are hereby generally and unconditionally authorised to exercise all or any of the powers of the Company to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company (“**Relevant Securities**”) up to an amount of 61,500,000 Ordinary Shares in relation to the issue of the Conditional Placing Shares, the Retail Offer Shares and the Warrants and including authority over 13,000,000 Ordinary Shares to provide flexibility to the Directors to take advantage of positive circumstances, should they arise, and raise further funds prior to the Company’s 2026 annual general meeting provided that this authority shall expire (unless previously renewed, varied or revoked by the Company in a meeting of Shareholders) at the conclusion of the annual general meeting of the Company to be held in 2026 save that the Company may before such expiry make an offer or agreement which would or might require Relevant Securities to be allotted after such expiry and the Directors may allot Relevant Securities pursuant to any such offer or agreement not withstanding such expiry.

SPECIAL RESOLUTION

2. That the Directors be and they are pursuant to Article 5.4 (a) of the Company’s articles of association hereby empowered to allot up to 61,500,000 Ordinary Shares in relation to the issue of the Conditional Placing Shares, the Retail Offer Shares and the Warrants and including authority over 13,000,000 Ordinary Shares to provide flexibility to the Directors to take advantage of positive circumstances, should they arise, and raise further funds prior to the Company’s 2026 annual general meeting for cash pursuant to the authority conferred by Resolution 1 as if the pre-emption rights in Article 5.3 (a) of the Company’s articles of association did not apply to any such allotment provided that the power hereby granted shall expire at the conclusion of the annual general meeting of the Company to be held in 2026, save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry, but otherwise in accordance with the foregoing provisions of this power in which case the Directors may allot equity securities in pursuance of such offer or agreement as if the power conferred hereby had not expired.

BY ORDER OF THE BOARD

Andrew Webb

Executive Chairman

Dated: 27 May 2026

Registered Office:

Kingston Chambers
P.O. Box 173
Road Town
Tortola
British Virgin Islands

Notes

1. To be valid, the enclosed Form of Proxy for the meeting convened by the above notice and any authority under which it is executed (or a notorially certified copy of such authority) must be deposited at the Company's registrars' office at MUFG Corporate Markets, PXS1, Central Square, 29 Wellington Street, Leeds, LS1 4DL to be received not less than 48 hours before the time for holding the meeting.

Alternatively, shareholders can vote electronically via the Investor Centre, a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below. Alternatively, you may access the Investor Centre via a web browser at: <https://uk.investorcentre.mpms.mufg.com/>.



Unless otherwise indicated on the Form of Proxy or any other electronic voting instruction, the proxy will vote as they think fit or, at their discretion, withhold from voting.

2. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the time by which a person must be entered on the register of members in order to have the right to vote is close of business BST on 11 June 2026 (being not more than 48 hours prior to the time fixed for the meeting) or, if the meeting is adjourned, such time being not more than 48 hours prior to the time fixed for the adjourned meeting. Changes to entries on the register of members after that time will be disregarded in determining the right of any person to vote.
3. In the case of joint holders, the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the relevant joint holding.
4. In the case of a corporation, the enclosed Form of Proxy must be executed under its common seal or be signed on its behalf by an attorney or officer duly authorised.
5. Depository Interest Holders wishing to vote in respect of the resolutions to be considered at the Shareholders' Meeting can do so by instructing the Depository. This may be done in the following ways:
 - (i) Depository Interest Holders who are CREST members may give such an instruction authorise the CREST electronic voting service in accordance with the procedures described in the CREST Manual. CREST personal Depository Holders or other CREST sponsored members, and those CREST members who have appointed a voting service provider, should refer to their CREST sponsor or voting service provider, who will be able to take the appropriate action on their behalf.

In order for an instruction made by CREST to be valid, the appropriate CREST message ("a CREST proxy instruction") must be properly authenticated in accordance with Euroclear's requirements and must contain information required for such instructions, as described in the CREST Manual. The message, in order to be valid, must be transmitted so as to be received by the Depository's agent, ID RA10 by 10.00 a.m. on 10 June 2026. The time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST applications host) from which the Depository's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. The Depository may treat as invalid a CREST voting instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST proxy instructions. It is the responsibility of the CREST member concerned to take (or to procure that his CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. Please refer to the CREST Manual for further guidance.
 - (ii) Depository Interest Holders who cannot give voting instructions via CREST should complete the enclosed Form of Direction and submit to the Depository. If the Depository Interest Holder is a corporation then the Form of Direction must be executed by a duly authorised person or under its common seal or in a manner authorised by its constitution. To be valid Forms of Direction must be received by the Depository no later than 10.00 a.m. on 10 June 2026.
 - (iii) If you are an institutional investor you may also be able to submit your instruction electronically via the Proximity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proximity, please go to www.proximity.io. Your instruction must be lodged by 10.00 a.m. on 10 June 2026 in order to be considered valid or, if the meeting is adjourned, by the time which is 72 hours before the time of the adjourned meeting. Before you can submit an instruction via this process you will need to have agreed to Proximity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic submission of your instruction. An electronic submission via the Proximity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your submission.

- (iv) To be effective, a valid form of direction (and any power of attorney or other authority under which it is signed) must be received electronically or delivered to MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL, by no later than 10.00 a.m. on 10 June 2026 or 72 hours before any adjourned meeting. You must be registered as holder of the Depository Interests as at close of business on 9 June 2026 (or 72 hours before any adjourned meeting) for your form of direction to be valid.
- (v) The Depository will appoint the Chair of the meeting as its proxy to cast its votes. The Chair of the meeting may also vote or abstain from voting as they think fit on any other business (including amendments to resolutions) which may properly come before the meeting. The 'Vote Withheld' option is provided to enable you to abstain from voting on the resolutions. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
- (vi) Depository interest holders wishing to attend the meeting should contact the Depository at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds, LS1 4DL or by emailing Nominee.Enquiries@cm.mpms.mufig.com by no later than 10.00 a.m. on 10 June 2026 or 72 hours before any adjourned meeting.